COVID-19 Vaccines

World Market Report

MCP16937

EXECUTIVE ENGAGEMENTS

POOL

11721
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

3992
Interactions with Platform & by Email

PARTICIPANTS

964
Unique # Participated

VALIDATIONS

103
Responses Validated*

COMPANIES

358
Responses Validated*
* Login for a full stack data experience

DATE

FEB 2022

TABLES

45

PAGES

762

EDITION

4

PRICE

USD 5800

CODE

MCP16937


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

STRONG ACTIVE NICHE TRIVIAL

%

VALIDATED RESEARCH *

S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year


After months of what seemed to be a receding pandemic supported by vaccines and adherence to new COVID appropriate protocols as the new normal, the world is witnessing the ghosts of the past rising once again. Barely months after the Indian strain called the Delta, or B.1.617.2 which was 40-60% more transmissible than Alpha and almost twice as transmissible as the original Wuhan strain of SARS-CoV-2 took over the world as a dominant strain, a new variant dubbed as "Omicron (B.1.1.529)" has emerged. Originally detected in South Africa in mid-November 2021, Omicron is now spreading across the globe with Asia, Europe, and North America reporting infections from this strain.

In addition to acquiring the mutations of the delta variant, the Omicron variant has over 50 mutations with 32 of them seen on its spike protein, two times higher than Delta, indicating that the virus has further adapted to the human species. Even more worrisome and unsettling is the fact that the variant also includes the vaccine-resistant alterations seen in Beta variant. The worst variant the pandemic has thrown up till date and carrying the mutations P681H and N679K, Omicron is feared to reduce vaccine effectiveness by close to 40% to 50%. There are fears that this strain is capable of outsmarting monoclonal antibodies, such as Regeneron`s treatment, since these therapies target parts of the virus that have now mutated. Currently classified as `variant of concern`, fears over the spreading Omicron have once again pushed countries across the globe to re-impose international and domestic travel restrictions. Omicron is now expected to displace the circulation Delta and other variants. It`s only a matter of time before a newer more competitive virus emerges. With Europe already battling fourth and fifth waves of infections, the new Omicron variant is bringing back ghosts of the past year. Fears are again rising over possible increase in infections, mortalities, overburdened hospitals, healthcare systems and lockdowns resulting in yet another economic nightmare. Lockdowns, travel and movement restrictions will be back once again if infection from this new strain fails to be controlled. India which is just recovering from the intense second wave with hopes of the disease reaching an endemic state, the new variant is reigniting fears of a possible third wave.

With several countries facing repeated waves of infections, the world is up against a new challenge in this war against the virus. An uphill challenge confronts governments in rapidly stepping up efforts to accelerate the pace of vaccine administration, despite numerous challenges. It`s a race against time and to successfully end the pandemic, mass vaccination drives must outpace the speed with which the coronavirus is currently mutating. Vaccine inequality is the prime reason behind the emergence of these new series of mutant strains which are more infectious, transmissible and responsible for resurgence of infection outbreaks worldwide. With the rise in vaccination rates especially in developed countries, measures designed to limit the spread of Covid-19 like mask mandates and capacity limits have been relaxed. The subsequent relaxation strengthened consumer confidence and allowed economic activity to return to normalcy. However, with the Covid-19 virus rapidly mutating, new variants have emerged in many parts of the world, posing a threat of potential future waves. Different parts of Europe are currently witnessing fourth and fifth waves of infection spread. These new variants are more deadly than the original virus, more easily transmissible and can impact the effectiveness of vaccines.

Prolonging pandemic and new mutant strains means that immunity among vaccinated population is beginning to slip, throwing the focus on booster doses. The leading vaccine makers, Pfizer-BioNTech, Moderna and AstraZeneca announced plans to pursue development of booster shots to address the emerging threat of new virus variants. The booster shot will be essential to keep the immune system to the optimum level. A number of wealthy countries like the US, Germany and Israel are considering booster shots to increase protection against Covid-19. Germany is expected to roll out booster shots to vulnerable individuals. mRNA-vaccines from Pfizer/BioNTech and Moderna will be offered as booster shots, regardless of the vaccine administered previously. In India, Bharat Biotech, the makers of Covaxin, received regulator`s approval for conducting trials for a third shot that will be administered as a booster dose. While a booster dose is typically an exact replica of the initial vaccine, it can also be tweaked. Moderna, AstraZeneca, Pfizer are working on variant-specific booster shots. Recently, Moderna announced positive initial data from its ongoing phase 2 study.

The data revealed that the booster dose increased neutralizing antibody responses against the original virus as well as B.1.351 and P.1, in previously vaccinated individuals. Studies suggest that a third dose can boost antibodies even in immunocompromised patients. The rapid pace at which new strains capable of evading antibodies are rising is throwing the focus on vaccine tweaking and researchers are already working on updating vaccines with the new spike proteins to prepare for new variants with a new version of the vaccine. This however requires additional clinical trials, more time consuming research work, and regulatory approvals. The time-to-market remains a main challenge with the process taking six to eight months before vaccines can be updated and commercialized. This time-consuming development process is a major setback when compared to the rapid rate of infection spread from new strains.

In this race against virus evolution, swift and rapid vaccinations are the need of the hour to limit the spread of mutant strains, notwithstanding the fact that vaccines themselves are contributing to virus mutations. Rapid mass vaccinations will make the mutation process and threat more manageable. It is an undeniable fact that vaccines will see a slow erosion in efficacy and effectiveness over the long-term. Therefore it is important to slow the spread of the virus by vaccinating as many people as possible at the earliest. To end the pandemic, which currently seems to have received yet another setback will require more dedicated focus on vaccine equality, international cooperation in COVID research, more transparent information transfer and alert systems on new emerging strains, waiver of IP on vaccines, and science-based swift decisions regarding travel bans. All of these are vital to prevent squandering away "hard won gains" achieved against the virus over the last 2 years.

SELECT PLAYERS

Moderna, Inc.; Pfizer Inc./BioNTech; AstraZeneca/University of Oxford; Johnson & Johnson ; CanSino Biologics, Inc.; China National Pharmaceutical Group Co., Ltd. (Sinopharm); Sinovac Biotech Ltd.; Novavax, Inc. ; Inovio Pharmaceuticals ; Sanofi/GlaxoSmithKline

SEGMENTS

» Age Group (18 Years & Above, Under 18 Years)

GEOGRAPHIES

» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Spain » Russia » Rest of Europe » Asia-Pacific » India » Rest of Asia-Pacific » Latin America » Brazil » Mexico » Rest of Latin America » Middle East » Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
Omicron Spreads Panic Worldwide; Omicron Variant Brings Back Memories & Fears of the Worst Part of the 2020 Pandemic
EXHIBIT 2: Time is of Essence! What We Know So Far – “Vaccine Efficiency Against New Strains is Decreasing”
South Africa: Omicron’s Origin Location
Omicron: Impact on Travel Industry
Countries that have Already Detected Omicron Cases
Steps taken by the Countries to Prevent Transmission of Omicron Variant
Fears of Tourism Industry
Industry Response to the Travel Curbs
Short-term Impact of Omicron on Travel
Financial Impact
Scientists Seek to Gather More Information on Omicron
Pharma Firms Aim to Improve Existing Vaccines to Counter Omicron
With New Strains Emerging at an Alarming Rate, Focus Shifts to Booster Doses & Vaccine Tweaking. But How Practical Is It to Implement Them?
EXHIBIT 2: With Vaccinated Population Showing Signs of Declining Clinical Protection, Booster Doses Are Emerging Into a Necessity to Restore Vaccine Effectiveness, but this Strategy is Not Within Reach for Most Countries: Number of Booster Doses Administered Per 100 People by Country as of December 2021
At the Dawn of 2022, We Leave Behind Millions of Deaths Due to New Strains & Once Again Stare at an Impending Catastrophe
Split Scenarios Unfold: The Great Vaccine Divide Emerges
Amid this Prolonged Pandemic, Why Should Businesses Care About Progress on Vaccinations?
With IMF Making an Upward Revision of Global GDP for 2021, Companies Are Bullish About an Economic Comeback Despite a Continuing Pandemic
Widening Revenue Gap between mRNA COVID-19 Vaccines & their Rivals
COVID-19 Vaccine Makers Set to Reap Rich Dividends from Booster Shots
Are COVID-19 Boosters Going to Follow Flu Shot Pattern?
Covid-19 Vaccine Shortages Hit Global Supply Initiative
Despite US Donation, Global Delivery of COVID-19 Vaccines Remains Far Short of Target
Anti-Vaccine Movement Poses Significant Threat
COVID-19 Vaccines – Global Key Competitors Percentage Market Share in 2022 (E)
THE VARIOUS COVID-19 VIRUS VARIANTS
Widening Revenue Gap between mRNA COVID-19 Vaccines & their Rivals
COVID-19 Vaccine Makers Set to Reap Rich Dividends from Booster Shots
Are COVID-19 Boosters Going to Follow Flu Shot Pattern?
Covid-19 Vaccine Shortages Hit Global Supply Initiative
Despite US Donation, Global Delivery of COVID-19 Vaccines Remains Far Short of Target
Anti-Vaccine Movement Poses Significant Threat
EXHIBIT 5: COVID-19 Cases Worldwide by Country: As on November 21, 2021
THE VARIOUS COVID-19 VIRUS VARIANTS
Emergence of Delta Variant Sparks New Wave of Infections
Is South African Variant a Formidable Threat?
E484K Mutation Challenges Vaccine Developers
California Strain Emerges to be More Contagious and Deadly
Is COVID-19 Virus Increasingly Resorting to Mutation to Outsmart Vaccines?
Less Effectiveness of AstraZeneca Vaccine Against South African Variant Leads to its Halt
Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant
US Government Unveils Covid-19 Vaccine Booster Shot Plan to Maximize Vaccine Protection Against Emerging Variants
AstraZeneca Vaccine Effective against New Emerging Variants
Sinovac Vaccines Effective against Mutated Variants of Coronavirus
AN OVERVIEW OF COVID-19 VACCINE ROLLOUT
COVID-19 Vaccine Approval Details
EXHIBIT 8: Production Capacity by Company for Frontrunners in Millions of Doses for 2021
COVID-19 Vaccine Funding Details
Pfizer/BioNTech’s COVID-19 Vaccine Receives World’s First Authorization
UK Clinches the First Position in the World to Approve Pfizer’s Vaccine
After UK, Pfizer’s Vaccine Gains Approval from the US and EU
UK Clinches the First Position in the World to Approve Pfizer’s Vaccine
After UK, Pfizer’s Vaccine Gains Approval from the US and EU
Novartis Inks Agreement with Pfizer-BioNTech to Support Covid-19 Vaccine Production
After Pfizer, Moderna Vaccine Bags Coveted EUA from US FDA
Moderna Kick-Starts Inoculation in the US
AstraZeneca’s Vaccine - Third Globally to Obtain Approval
J&J’s Single Shot Vaccination Resumes after Temporary Suspension
Pfizer/BioNTech vs. Moderna vs. AstraZeneca vs. J&J Vaccine
A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
Johnson & Johnson's Adenovirus-based COVID-19 Vaccine vis-a-vis Moderna or Pfizer
Russia Commences Mass Vaccination from Mid-December, 2020
China Awards Conditional Approval to First COVID-19 Vaccine from Sinopharm
WHO Approves China`s Sinopharm Covid-19 vaccine for Emergency Use
China Issues License for Vaccine Production to Overseas Partners
Brazilian Authorities Approve Sinovac’s CoronaVac
AstraZeneca’s Covishield and Bharat Biotech’s Covaxin Receive Emergency Use Approval in India
Sanofi-GSK to Offer Vaccine at a Discounted Rate
CanSinoBIO Claims No Blood Clot Issues from COVID-19 Vaccine
Novavax Obtains First Authorization for its COVID-19 vaccine
VARIOUS COVID-19 VACCINES UNDER CLINICAL TRIALS
EXHIBIT 9: COVID-19 VACCINES UNDER DEVELOPMENT
EXHIBIT 11: Vaccines in Pipeline by Technology
EXHIBIT 12: Vaccine Technologies in Pre-Clinical Studies
mRNA: A NEW APPROACH TO MEDICINE
mRNA Vaccine Marks Dawn of New Era of Vaccines & Medical Therapies
RNA Technology: Benefits & Potential for Future Outbreaks
Key Challenges
mRNA Vaccines Could Vanquish COVID-19 and Cancer
Efforts to Target New Application Areas
MARKET DYNAMICS
Rise of Vaccine Passports: Key to Ease COVID-19 Restrictions & Ensure Public Safety
Developments Regarding Digital Certificates
COVID-19 Vaccine Passport: Insights & Progress
mRNA Vaccines Offer More Protection Against Newer Variants
Vaccine Companies Stress on Booster Dose
Longer Interval between the Two Doses of Pfizer Vaccine to Boost Antibody Levels
Mix and Match is the New COVID-19 Vaccine Mantra
Long-Haul COVID-19 Holds Potential to Become a Public Health Issue
Vaccine Alliances Ensure Supplies for All
EXHIBIT 13: Select Funding Deals for COVID-19 Vaccine R&D: 2020 & 2021
Licensing and Partnership Deals Worldwide Propel Vaccine Production
EXHIBIT 14: COVID-19 Deals Worldwide - Jan 2020 to July 2021
GLOBAL MARKET PERSPECTIVE
EXHIBIT 15: Global Percentage of Individuals Vaccinated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India, Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), Middle East and Africa Markets - Independent Analysis of Percentage of Individuals Vaccinated for 2020 through 2025
EXHIBIT 16: European Percentage of Individuals Vaccinated by Geographic Region - France, Germany, United Kingdom, Italy, Russia, Spain, and Rest of European Markets - Independent Analysis of Percentage of Individuals Vaccinated for 2020 through 2025
EXHIBIT 17: Global Number of Annual COVID-19 Vaccine Doses (In Million) for Years 2020 through 2025 by Geographic Region/Country - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets
EXHIBIT 18: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025
EXHIBIT 19: World Current & Future Analysis for COVID-19 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets - Independent Analysis of Annual Doses in US$ Million for Years 2020 through 2025
EXHIBIT 20: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025
VACCINES FOR KIDS
Kids: A Key to COVID-19 Controlling Efforts
US FDA Approves Pfizer-BioNTech Vaccine in Kids aged 5-11 Years, and 12 to 15 Years Age
Pfizer Approves Vaccine for Kids Aged 5-11 Years
Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
Oxford University Halts AstraZeneca COVID-19 Vaccine Trial on Children over Perceived Safety Concerns
COVID-19 Vaccine Spikevax Approved for Children aged 12 to 17 in EU
REGIONAL MARKET PERSPECTIVE
THE UNITED STATES
MARKET ANALYSIS
MARKET ANALYTICS
CANADA
MARKET ANALYSIS
MARKET ANALYTICS
JAPAN
MARKET ANALYSIS
MARKET ANALYTICS
CHINA
MARKET ANALYSIS
MARK¬ET ANALYTICS
EUROPE
Covid-19 Scenario in Europe, Rise in Cases Noted
New Covid-19 Variants
Skepticism Regarding the Vaccination
Europe Witnesses Increase in COVID-19 Cases, Turns to Booster Doses
EMA Approves Use of COVID-19 Vaccine of Pfizer for Children
EU to Recommend 9-MonthTime Limit for COVID-19 Vaccine Validity for Travelers
EU Digital COVID Certificate Regulation to Aid Free Cross-Border Movement
EU Digital COVID Certificate: Eligibility, Process & Free Movement
Pfizer & Moderna Escalate Unit Price of COVID-19 Vaccines in Latest EU Contracts
EU Obtains 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine
European Agency Makes Changes to Ramp Up Supply & Manufacturing Capacity of Pfizer & Moderna COVID-19 Vaccines
BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
Europe’s Horizon 2020
EC-AstraZeneca Settlement Deal Ends Legal Dispute over COVID-19 Vaccine Supplies
Johnson & Johnson to Resume Shipment of Janssen COVID-19 Vaccine to Europe
Apparent Side-Effects Prompt Denmark to Extend Suspension of Oxford-AstraZeneca COVID-19 Vaccine
MARKET ANALYSIS
MARKET ANALYTICS
ASIA-PACIFIC
MARKET ANALYSIS
MARKET ANALYTICS
THE MIDDLE EAST
MARKET ANALYSIS
MARKET ANALYTICS
AFRICA
MARKET ANALYSIS
SOUTH AFRICA
EGYPT
MARKET ANALYTICS
LATIN AMERICA
MARKET ANALYSIS
MARKET ANALYTICS
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
FOCUS ON THE FRONTRUNNERS
Moderna, Inc. (USA)
Pfizer Inc./BioNTech (US/Germany)
AstraZeneca/University of Oxford (The UK)
Johnson & Johnson (USA)
CanSino Biologics, Inc. (China)
China National Pharmaceutical Group Co., Ltd. (Sinopharm) (China)
Sinovac Biotech Ltd. (China)
Novavax, Inc. (USA)
Inovio Pharmaceuticals (USA)
Sanofi/GlaxoSmithKline (France/UK)
INITIATIVES FOR EQUITABLE DISTRIBUTION OF VACCINES
Fair Distribution of COVID-19 Vaccine
Vaccine Nationalism Hampers Equitable Distribution of Vaccines
COVAX Created to Ensure Fair and Universal Access to COVID-19 Vaccine
COVAX Inks Additional Deals for Global Rollout of COVID-19 Vaccines
African Countries Become Part of the COVAX Facility for Timely Access to Successful Vaccines
COVAX Advance Market Commitment (AMC)
World Economic Forum to Push COVID-19 Vaccine Production Capability
Pushing Manufacturing Capacity to Fulfil Global Demand
Technology Transfer and Other Payments
KEY VACCINE TECHNOLOGY PLATFORMS
Inactivated Vaccines
Inactivated Vaccine Candidate in Preclinical Development: As on Nov 19, 2021
Protein-Subunit Vaccines
Protein-Subunit Vaccine Candidate in Preclinical Development: As on Nov 19, 2021
Non-Replicating Viral-Vector
Non-Replicating Viral Vector Vaccine in Preclinical Development: As on Nov 19, 2021
Replicating Viral Vector Vaccine Candidate in Preclinical Development: As on Nov 19, 2021
Nucleic Acid Vaccines
RNA Vaccine Candidate in Preclinical Studies: As on Nov 19, 2021
DNA Vaccine Candidate in Preclinical Studies: As on Nov 19, 2021
Replicating Bacteria Vector
Live Attenuated Vaccines (LAVs)
Live Attenuated Virus Candidate in Preclinical Studies: As on Nov 19, 2021
Live Attenuated Bacterial Vector Candidate in Preclinical Studies: As on Nov 19, 2021
Virus-like Particle Vaccines
Virus-like Particles (VLP) Vaccine Candidate in Preclinical Development: As on July 27, 2021
WORLD COVID-19 VACCINE BRANDS
SELECT CORPORATE DEVELOPMENTS IN THE COVID-19 VACCINE MARKET: 2021
Total Companies Profiled: 358

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com